Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy
International Journal of Nanomedicine · 2025-03 · Volume 20 · 3789-3802
DOI: 10.2147/ijn.s486488 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2025-03. Verfasst von Huan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, People's Republic of China. Hauptthemen laut MEDLINE: Liposomes, Dexamethasone, Arthritis, Rheumatoid, Peptides. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Delivering the anti-inflammatory dexamethasone in nanoformulations is important for reducing off-target effects when treating rheumatoid arthritis. Nanoformulations can be targeted to sites of inflammation by modifying the nanoparticles with albumin before administration, but such particles can be unstable in vivo.
Methods
Here, we have developed and validated an alternative targeting in which dexamethasone-loaded liposomes were modified with a 46-residue peptide called "albumin-binding domain", such that the liposomes would adsorb endogenous albumin after administration.
Results
The resulting liposomes were small (90 nm diameter) and uniformly dispersed, and both X-ray diffraction and differential scanning calorimetry confirmed efficient dexamethasone encapsulation. Functionalizing the liposomes with albumin-binding peptide strongly increased not only their binding to albumin in vitro but also their uptake by RAW264.7 cells in culture. After injection into rats with adjuvant-induced arthritis, the liposomes accumulated and persisted at sites of inflammation, effectively inhibiting joint swelling and reducing the level of the inflammatory factors TNF-α and IL-1β in joints. The liposomes decorated with the albumin-binding peptide did not display obvious hepatotoxicity and did not reduce red and white blood cells number.
Discussion
Our results validate modifying liposomes with albumin-binding domain as a way to target them to sites of inflammation for efficient drug delivery against rheumatoid arthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, People's Republic of China.
- Key Laboratory of Coarse Cereal Processing (Ministry of Agriculture and Rural Affairs), School of Food and Biological Engineering, Chengdu University, Chengdu, 610106, People's Republic of China.
- Department of Hepatobiliary & Pancreatic Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, People's Republic of China.
Zitieren
APA
Wang, H., Gou, R., Li, W., Chen, Z., Gu, C., Shi, S., Zou, L., & Li, H. (2025). Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy. International Journal of Nanomedicine, Volume 20, 3789-3802. https://doi.org/10.2147/ijn.s486488
Vancouver
Wang H, Gou R, Li W, Chen Z, Gu C, Shi S, et al. Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy. International Journal of Nanomedicine. 2025;Volume 20:3789-3802. doi:10.2147/ijn.s486488
BibTeX
@article{Wang2025,
author = {Wang, Huan and Gou, Rui and Li, Wei and Chen, Zhoujiang and Gu, Chun and Shi, Sanjun and Zou, Liang and Li, Hanmei},
title = {Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy},
journal = {International Journal of Nanomedicine},
year = {2025},
volume = {Volume 20},
pages = {3789--3802},
doi = {10.2147/ijn.s486488}
}
EUVIMED